$4.09
0.277.07%
Last update: Nov 9, 5:07 PM
Vanda Pharmaceuticals Inc
VNDANASDAQ
Vanda Pharmaceuticals fell 7.5% from $4.42 to $4.09, behind the S&P 500's +10.5%. Its worst day was Feb 12 (−17.6%), and its low came Nov 5 at $3.59.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Vanda Pharmaceuticals shares rose 21.6%, while the S&P 500 fell 0.8%.
+21.6% · S&P 500 −0.8%
Story events cover the past 12 months · Times ET
Vanda Pharmaceuticals shares rose 25.5%, while the S&P 500 fell 0.7%.
+25.5% · S&P 500 −0.7%
Vanda Pharmaceuticals shares fell 14.1%, while the S&P 500 fell 0.0%.
−14.1% · S&P 500 0.0%
EPS of $-2.39 missed the $-1.67 estimate on $57.2M revenue (est. $59.1M); FY revenue guidance of $230.0M–$260.0M against the $273.1M consensus.
−17.6%, the year's worst day · S&P 500 −1.5%
Vanda Pharmaceuticals shares rose 41.5%, while the S&P 500 fell 1.0%.
+41.5%, the year's best day, on 48M shares, the year's heaviest volume · S&P 500 −1.0%
Vanda Pharmaceuticals closed at its highest level of the year, 116.3% above where the year started.
+10.1% · S&P 500 −0.2%
Vanda Pharmaceuticals shares fell 16.9%, while the S&P 500 fell 1.4%.
−16.9% · S&P 500 −1.4%
EPS of $-0.82 missed the $-0.66 estimate on $51.7M revenue (est. $54.7M); FY revenue guidance of $240.0M–$290.0M against the $257.4M consensus.
−14.1% · S&P 500 −0.3%
EPS of $-1.04 missed the $-0.57 estimate on $50.5M revenue (est. $62.1M); FY revenue guidance of $240.0M–$290.0M against the $261.5M consensus.
+0.5% · S&P 500 −0.2%
EPS of $-0.37 beat the $-0.69 estimate on $69.8M revenue (est. $68.5M); FY revenue guidance of $240.0M against the $248.0M consensus.
+1.2% · S&P 500 −0.4%
Where it ended: a close of $4.09 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 10, 2027 (EPS est. $-0.31, revenue est. $70.0M).
Nothing in the past 12 months.
All VNDA dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for VNDA and SPY from Benzinga historical bars. Not investment advice.
